Company Overview and News
Otonomy Inc (NASDAQ:OTIC) magnetized Street-wide attention after Wednesday's triumphant Phase III home run in Meniere's, leading investors to send the stock racing up 83% in value. SunTrust analyst Edward Nash sees a meaningful value driver ahead by the first quarter of 2018, bullish on Otividex's clinical trajectory ahead. (97-2)
Good day, ladies and gentlemen. And welcome to the Otonomy Incorporated Third Quarter 2017 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time [Operator Instructions]. As a reminder, this conference call maybe recorded. (125-1)
The following slide deck was published by Otonomy in conjunction with their 2017 Q3 earnings call. (97-0)
The biotech sector continues to head down this week as sentiment on the high beta areas of the market weaken. (159-1)
Otonomy Inc. (NASDAQ: OTIC) reported its most recent quarterly results after the markets closed on Wednesday and gave an update on its late-stage trial in patients with Ménière’s disease. Although earnings were fairly positive, this Phase 3 trial was what really skyrocketed shares. (97-1)
Over the last six months, Fennec has uplisted, raised $7.6M above market, and released positive Phase 3 data. (102-5)
If you want a Stock Review on OPK, OTIC, PACB, or PTLA then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Zacks reported that despite some challenges in 2016, it sees the trend reversing for the Biotech space in 2017 with more FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results, and continued strong performance of some legacy products. (258-4)
Recent announcement of a Phase III failure and subsequent shuttering of a major drug program, Otividex, has significantly lowered OTIC's stock price. (97-5)
SAN DIEGO, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced a set of immediate actions to preserve capital, extend its cash runway, and build shareholder value following the recent negative AVERTS-1 Phase 3 trial results for OTIVIDEX in Ménière’s disease. (0-1)
Otonomy, Inc. (NASDAQ:OTIC) has 91 institutional investors that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 23,149,457 shares. Major holders include Wellington Management Group Llp, BlackRock Inc., TPG Group Holdings (SBS) Advisors, Inc., Federated Investors Inc /pa/, and Orbimed Advisors Llc.
The biotech sector continues to be range bound in trading as it consolidates its large gains from a June rally.
Good day, ladies and gentlemen, and welcome to the Second Quarter Otonomy, Increase Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session and instructions will be given at that time. [Operator Instructions].
Investors in Otonomy, Inc. (OTIC - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the October 20th, 2017 $20.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
Investors in Otonomy, Inc. (OTIC - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the December 15th, 2017 $20 Call had some of the highest implied volatility of all equity options today.
Stock Research Report
Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIOâ (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement (TTP) surgery in pediatric patients, has achieved positive pivotal trial results in patients with acute otitis externa (AOE), and has completed a successful Phase 2 trial in patients with acute otitis media with tubes (AOMT). OTO-104 is a steroid in development for the treatment of Ménière’s disease and other severe balance and hearing disorders. Two Phase 3 trials in Ménière’s disease patients are underway with results expected during the second half of 2017, and a Phase 2 trial has been initiated in patients at risk for cisplatin-induced hearing loss. OTO-311 is a N-Methyl-D-Aspartate (NMDA) receptor antagonist for the treatment of tinnitus that has completed a Phase 1 clinical safety trial with a Phase 2 trial expect...
2017-10-28 - Wilton
2017-10-25 - Wilton
2017-10-10 - Wilton
2017-10-09 - Wilton
2017-08-25 - Wilton